Paul Rennert

Company: Aleta Biotherapeutics

Job title: President & Chief Scientific Officer

Bio:

Paul is a noted scientist and biotechnology executive with strong strategic and leadership experience. His industry expertise covers bench to IND and clinical trial development of small molecule drugs, biologics, and cellular therapeutics. His recent accomplishments include the launch of successful new biotech companies. In 2012 he engaged in the strategic analysis of cancer immuno-therapeutics with CoStim Pharmaceuticals’ executive and investment team to prioritize and launch that company’s program portfolio. In 2013 he partnered with X-Chem Inc to create XRx Discovery, a privately held drug discovery company focused on oncology, inflammation, and fibrosis. In 2016 he co-founded Aleta Biotherapeutics, a novel CAR T cell company that has since moved from bench to clinical development in under 4 years. He is deeply engaged in the biotech community, as a MassBio and ASGCT mentor, by serving on diverse Boards and as a highly sought speaker and panelist in the IO, cell therapy and investment communities. His ability to work so broadly across the industry grew from his outstanding early career at Repligen and Biogen and is further highlighted by his multiple successful drug-development campaigns, over 50 patents filed and granted, and approximately 100 peer-reviewed publications including recent publications in Nature Reviews Drug Discovery, Immunity, PNAS USA, and JCI. In 2015 he edited the book “Novel Therapeutic Approaches to the Treatment of Cancer.